<DOC>
	<DOC>NCT00470145</DOC>
	<brief_summary>SB-568859 is a medication that is being developed for the treatment of atherosclerosis (hardening of the arteries). The purpose of this study is to see if there is a difference in how the human body takes up the study drug depending on how the study drug is made. This study will compare SB-568859 tablets that are made in 2 different ways. This is not a treatment study.</brief_summary>
	<brief_title>Comparison Of Two Tablet Formulations Of SB-568859</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Healthy men and sterile women between 18 and 50 years old Body weight greater than 50 pounds and a body mass index between 19 and 31 Normal electrocardiogram Exclusion criteria: No history of asthma or severe allergic reactions No history of or current drug use No Hepatitis or HIV/AIDS No excessive alcohol use No smoking or tobacco use No use of prescription drugs, overthecounter drugs or vitamins within 7 days No use of herbal supplements within 14 days No treatment with an investigational drug within 30 days. No treatment with 4 or more investigational drugs in the last 12 months No grapefruit or grapefruit juice in the last 7 days No donation of blood in the last 8 weeks No history of allergy to heparin No history of liver or gall bladder disease Unwillingness to use contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>unmilled formulation,</keyword>
	<keyword>micronised formulation</keyword>
	<keyword>relative bioavailability,</keyword>
</DOC>